Vitamin D Effects on GH, IGF-1, Glycemic Control Indicators, and Lipid Profile in Gestational Diabetes Mellitus

Abstract

Gestational diabetes mellitus is an unfavorable outcome in some pregnancies, which its prevalence has increased in the world in recent years. The present study is designed and performed to evaluate the effects of oral supplementation of vitamin D on the metabolic condition of expectant women suffering from gestational diabetes. In the present double-blind randomized clinical trial study, 36 women suffering from gestational diabetes in the range of 18-40 years were randomly divided into two groups. People in the vitamin D group (n=15) got a single dose of 2000 IU/d vitamin D during six weeks of intervention, and the people in the control group (n=15) similarly got placebo. Blood specimens of the persons were taken as fasting once at the research beginning and once at the termination of the sixth week of intermediation. In total, 30 participants were entered into the fmal analysis. In the vitamin D group, it was found a significant decrease in FPG (-0.4 +/- 10 vs -14.8 +/- 14.4, p=0.004), insulin (-0.2 +/- 1 vs -0.7 +/- 1.2, p=0.03) and HOMA-IR (-0.4 +/- 0.3 vs 0.1 +/- 0.4, p=0.001) and a significant enhancement in HOMA_B (184.5 +/- 120 vs -4.2 +/- 105, p<0.001) and QUICKI (0.009 +/- 0.008 vs -0.003 +/- 0.008, p<0.001) in comparison to the control group. Vitamin D3 supplementation had no significant impact on serum contents of total cholesterol, triglyceride, LDL, HDL, IGF-1, and growth hormone levels. Supplementation with 2000 IU vitamin D3 for six weeks has positive effects on glycemic condition control in expectant women suffering from GDM but does not affect the lipid profile, growth hormone, and IGF-1 levels, in them.